There are also problems associated with PPIs.
PPIs should have a black box warning.
"Compounding the problem of massive inappropriate use, recent evidence has documented several serious new safety problems with long-term PPI use. For some of these risks, current FDA-approved PPI labels do not mention the adverse effect at all, including the potential for developing dependence on the drugs, which results in rebound hypersecretion of stomach acid and recurrence of symptoms after stopping PPI use.
For other risks, even if mentioned, the label does not adequately explain or emphasize them. There are currently no black box warnings in the label of any PPI.
This petition outlines the current state of evidence of the risks involved with short- and long-term use of PPIs and asks that the FDA make prescribers and consumers aware of these risks through the following labeling changes."
http://www.medicalnewstoday.com/articles/233272.php
Case reports of hypomagnesaemia
Severe hypomagnesaemia has been reported infrequently in patients treated with PPIs, although the exact incidence is unknown. A review of case reports described in the literature or reported to regulatory authorities in Europe suggests that PPIs may cause hypomagnesaemia. Some cases occurred after 3 months of PPI therapy, but most occurred after 1 year of treatment. Serious manifestations of hypomagnesaemia—fatigue, tetany, delirium, convulsions, dizziness, and ventricular arrhythmia—can occur, but they may begin insidiously and be overlooked. In most case reports, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI.
For patients expected to be on prolonged treatment, and especially for those who take PPIs with digoxin or drugs that may cause hypomagnesaemia (eg, diuretics), healthcare professionals should consider measuring magnesium levels before starting PPI treatment and repeat measurements periodically during treatment.
http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON149774